Evaluation of the Effect and Side Effect of Tyrosine Kinase Inhibitors on the Treatment of Metastatic Renal Cell Carcinomas Metastatik Renal Hücreli Kanser Tedavisinde Tirozin Kinaz İnhibitörlerinin Etki ve Yan Etkisinin Değerlendirilmesi
Journal of Uludag University Medical Faculty, cilt.51, sa.1, ss.75-79, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.32708/uutfd.1593775
- Dergi Adı: Journal of Uludag University Medical Faculty
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.75-79
- Anahtar Kelimeler: Metastatic renal cell carcinoma, Prognostic factors, Retrospective analysis, Tyrosine kinase inhibitors, VEGF inhibitors
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
This study aims to retrospectively evaluate the efficacy and side effects of tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell carcinoma (mRCC). mRCC is a type of cancer diagnosed at advanced stages and significantly limits life expectancy. In Turkey, interferon-alpha has traditionally been used as a first-line treatment; however, targeted therapies such as TKIs have become a priority for patients showing progression. In the study, 65 patients who were diagnosed with mRCC and treated with TKI between 2010 and 2018 were examined. This retrospective analysis evaluated the demographic and clinical data of patients and their response to treatment. Key findings indicated that the survival outcomes of sunitinib and pazopanib treatments were consistent with the literature, with fatigue, hypertension, and dermatitis being prominent side effects. The average survival duration was calculated as 26 months. The results of the study support the effectiveness of TKIs in the treatment of mRCC and suggest that their impact could be better understood through prospective studies involving larger patient cohorts in the future.